Approximately 10%-20% of ovarian cancer patients have pathogenic or likely pathogenic germline variants (formerly called mutations) in BRCA1 or BRCA2 genes10,11 and ∼50% have somatic (tumor) defects in the homologous recombination repair pathway [homologous recombination deficiency (HRD)].10 The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.